Migraine Preventive Treatment
For episodic migraine, initiate treatment with propranolol, topiramate, or a CGRP-targeted therapy (monoclonal antibodies or gepants) as first-line options, with the choice guided by comorbidities, cost considerations, and patient preference. 1
First-Line Treatment Options for Episodic Migraine
The 2025 American College of Physicians guideline establishes that multiple pharmacologic options are effective for episodic migraine prevention, though all recommendations carry conditional strength due to low-certainty evidence 1. The most robust first-line options include:
Traditional Preventive Medications
- Propranolol remains a cornerstone first-line agent with established efficacy for episodic migraine prevention 1, 2, 3
- Topiramate is recommended as first-line therapy, though recent guidelines have downgraded it to a weak recommendation due to tolerability concerns 4, 3
- Metoprolol (another beta-blocker) has strong supporting evidence 2
- Candesartan (angiotensin receptor blocker) demonstrates effectiveness 2
CGRP-Targeted Therapies as First-Line
CGRP-targeting therapies should now be considered first-line options without requiring prior failure of other preventive classes 5. This represents a paradigm shift in migraine prevention:
- Monoclonal antibodies: Erenumab, fremanezumab, galcanezumab, and eptinezumab have substantial evidence exceeding that of traditional preventives 5, 6
- Oral gepants: Atogepant and rimegepant are approved for prevention with favorable safety profiles 5, 6
- These agents demonstrate equal or greater efficacy and tolerability compared to traditional first-line therapies, with rare serious adverse events 5
- The American Headache Society position statement explicitly supports CGRP-targeted therapies as first-line without mandating prior treatment failures 5
Chronic Migraine Prevention
For chronic migraine (≥15 headache days per month), the evidence-based first-line options differ:
- Topiramate is recommended as first-line for chronic migraine, particularly cost-effective 7, 3
- OnabotulinumtoxinA has proven effectiveness and is first-line for chronic migraine 7, 3
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) are first-line options with strong evidence 7, 3
Important caveat: Beta-blockers, candesartan, and amitriptyline lack robust randomized controlled trial data for chronic migraine prevention, though they are commonly used in clinical practice 7
Tailoring Treatment to Comorbidities
Comorbid conditions should drive medication selection to maximize benefit 7:
- Obesity: Topiramate is preferred due to associated weight loss 7
- Depression or sleep disturbances: Amitriptyline is most beneficial 7
- Anxiety: Consider venlafaxine 2
- Hypertension: Beta-blockers or candesartan provide dual benefit 2
Indications for Starting Prevention
Initiate preventive treatment when 3:
- Headache frequency ≥4 days per month
- Profound disability despite acute treatment
- Failure of or contraindication to acute therapies
- Complicated migraine with debilitating auras (e.g., hemiplegic)
- Migrainous brain infarction
Treatment Principles and Duration
Dosing Strategy
- "Start low and go slow" with oral preventives while monitoring for adverse events 3
- An adequate trial requires 2 months at target dose before assessing efficacy 2
- CGRP-targeted therapies may require longer treatment periods (beyond 12 weeks) in patients with higher baseline migraine days or prior treatment failures 8
Treatment Duration
- For episodic migraine: Consider tapering after sustained improvement over 3-6 months 3
- For chronic migraine: Continue for 6-12 months before considering taper 3
- Long-term management should transition to primary care with coordinated follow-up 7
Critical Pitfalls to Avoid
Medication Overuse Headache (MOH)
- Educate all patients about the risk of MOH with frequent acute medication use 7
- MOH frequently mimics chronic migraine and must be ruled out before initiating prevention 7
- Manage established MOH through explanation and withdrawal (abrupt withdrawal preferred except for opioids) 7
Risk Factor Modification
Recognize and modify risk factors for transformation to chronic migraine 7:
- High headache frequency
- Inadequate acute treatment
- Overuse of acute medications
- Depression, anxiety, obesity
Second and Third-Line Options
When first-line treatments fail or are contraindicated 1, 2, 3:
Second-line: Valproic acid, amitriptyline, venlafaxine, lisinopril
Third-line (weak recommendations): Memantine, levetiracetam, enalapril, melatonin 4
Weak recommendation against: Gabapentin for episodic migraine 4
Special Populations
Menstrual Migraine
Short-term prophylaxis with NSAIDs or triptans can be used during the perimenstrual period 3
Chronic Migraine Requiring Specialist Care
Referral to specialist care is usually necessary for chronic migraine management 7